American Cancer Society Journals

New this week in Cancer 📗 Top advances of the year: Reappraisal of systemic versus local therapy for hepatocellular carcinoma https://lnkd.in/eG3y4Jya Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide. The most recent global cancer burden estimated almost 760,000 deaths in 2022 alone. This commentary, led by Dr. Mosunmoluwa Oyenuga and Winship Cancer Institute of Emory University colleagues, summarizes past-year advances in systemic therapy options and emerging data regarding combinations with locoregional therapies for HCC. Additional insight into optimal treatment of unique populations and continued development of novel therapeutics are also highlighted. Full author list: Mosun Oyenuga, MD MPH, Tia McGrew PharmD, Lindsay Hannan MD MSc, and Olatunji Alese MD FWACS FASCO OncoAlert #HPBCSM #LiverCancer #LiverCancerTreatment #LiverCancerResearch

CA: A Cancer Journal for Clinicians celebrates 75 years in publication! 📕🎉 First published in 1950 as CA: A Bulletin of Cancer Progress, CA has grown into the flagship journal of the American Cancer Society and today holds the highest impact factor of any medical or scientific journal, inside and outside of oncology. Across its 75-year history, CA has upheld the American Cancer Society’s mission by sharing trusted, authoritative information about cancer with clinicians and researchers worldwide dedicated to improving patient care and outcomes. Looking ahead, CA aims to expand its scope by publishing more phase 3 trials that inform standards of care and by introducing consensus guidelines that offer expert perspectives on the management of diverse areas across oncology. Read reflections from Editor-in-Chief Dr. Don S. Dizon and the Editorial Board on CA’s 75-year journey: https://lnkd.in/ez-b-6kt Full author list: Don S. Dizon MD, Sumanta Pal, MD, FASCO, Banu Symington MD, MACP, Razelle Kurzrock MD, Arif Kamal MD, MBA, MHS, Christina Annunziata MD, PhD, Shanthi Sivendran MD, MSCR, MBA, FASCO, Ahmedin Jemal DVM, MPH, William Dahut MD

📗 CANCER is pleased to share a new supplement from the National Cancer Institute (NCI) Cancer Treatment Tolerability Consortium. It features eight articles that examine new methods for assessing cancer treatment tolerability. This work highlights how integrating clinician- and patient-reported data can deepen understanding of how treatment side effects affect patient experiences, decision-making, and outcomes. 🎥 Watch lead author Amylou Dueck PhD summarize the issue's contents, and explore the full supplement here: https://lnkd.in/eVTHFegf #CancerTreatment #ClinicalOncology #CancerResearch #Tolerability #PatientReportedOutcomes OncoAlert

Rising cancer rates in low- and middle-income countries (LMICs) aren’t being matched by growth in clinical research. A new study in Cancer, a peer reviewed journal of the American Cancer Society, highlights uneven development of cancer clinical trials across LMICs over the past 20 years. Key findings: 💠 Strong growth with economic gains: China, Egypt, South Korea 💠 Inconsistent growth despite economic gains: India, South Africa, Thailand, Vietnam 💠 Growth despite relative economic stagnation: Argentina, Brazil, Mexico Economic gains support trial expansion in some countries, but aren't the only factor shaping clinical trial activity in LMICs. These insights can help LMICs strategize for more equitable and effective clinical research. Read the full study: https://lnkd.in/eYkbzv_Z Full author list: Fanny G.A. Cascelli, Milene C. Mitsuyuki, Gustavo Werutsky, Carlos H.E. Barrios, Malu Viter R. Barbosa, Michelle S. Almeida, and Max S. Mano, MD, PhD OncoAlert LACOG - Latin American Cooperative Oncology Group #CancerResearch #GlobalHealth #HealthEquity #ClinicalTrials #GlobalOncology #ESMO25

Good Morning America has featured the new American Cancer Society (ACS) special report on lobular breast cancer incidence in 2025. The report is published in Cancer, an international interdisciplinary journal of ACS. 📺 Watch the coverage on YouTube: https://lnkd.in/ewZ_wVGE 📄 Read the full publication in Cancer: https://lnkd.in/ev3_uMA9 Congratulations to the authors Angela Giaquinto MSPH, Rachel Freedman, MD, MPH, Lisa Newman MD, MPH, Ahmedin Jemal DVM, PhD, and Rebecca Siegel MPH on this impactful work advancing our understanding of lobular breast cancer. OncoAlert

A new American Cancer Society special report reveals that lobular breast cancer, or invasive lobular carcinoma (ILC), is on the rise for women in the United States. Key findings: ✔ ~11% of U.S. breast cancers are ILC ✔ Incidence rising faster than other breast cancers ✔ ~33,600 U.S. diagnoses expected in 2025 ✔ Tumors tend to be larger at diagnosis and have lower long-term survival in advanced cases “Our study underscores the need for much more information on lobular cancers across the board, from genetic studies to clinical trial data, so we can improve outcomes for the increasing number of women affected with this cancer,” said Rebecca Siegel, MPH, senior scientific director of cancer surveillance research at the American Cancer Society and senior author of the study. Next steps for research and care: ✔ Raise awareness of ILC’s unique clinical features ✔ Prioritize research on detection & treatment strategies ✔ Ensure equitable care & access across all breast cancer subtypes Read the full #OpenAccess study: https://lnkd.in/e-RDXB-D #CancerResearch #WomensHealth #BCAM #BreastCancerResearch Full author list: Angela Giaquinto MSPH, Rachel Freedman, MD, MPH, Lisa Newman MD, MPH, Ahmedin Jemal DVM, PhD, and Rebecca Siegel MPH OncoAlert

A new American Cancer Society special report reveals that lobular breast cancer, or invasive lobular carcinoma (ILC), is on the rise for women in the United States. Key findings: ✔ ~11% of U.S. breast cancers are ILC ✔ Incidence rising faster than other breast cancers ✔ ~33,600 U.S. diagnoses expected in 2025 ✔ Tumors tend to be larger at diagnosis and have lower long-term survival in advanced cases “Our study underscores the need for much more information on lobular cancers across the board, from genetic studies to clinical trial data, so we can improve outcomes for the increasing number of women affected with this cancer,” said Rebecca Siegel, MPH, senior scientific director of cancer surveillance research at the American Cancer Society and senior author of the study. Next steps for research and care: ✔ Raise awareness of ILC’s unique clinical features ✔ Prioritize research on detection & treatment strategies ✔ Ensure equitable care & access across all breast cancer subtypes Read the full #OpenAccess study: https://lnkd.in/e-RDXB-D #CancerResearch #WomensHealth #BCAM #BreastCancerResearch Full author list: Angela Giaquinto MSPH, Rachel Freedman, MD, MPH, Lisa Newman MD, MPH, Ahmedin Jemal DVM, PhD, and Rebecca Siegel MPH OncoAlert

Fatigue is one of the most frequent and challenging symptoms for people with cancer. New work from researchers at UCLA Health suggests that inflammation may contribute to different types of cancer-related fatigue. The study finds that in women with early-stage breast cancer: 💠Certain inflammatory markers were linked to general tiredness and physical weakness 💠 Some markers were linked to lower emotional fatigue 💠 No clear connection was found with mental fatigue “Our findings indicate that inflammation plays a role in some aspects of cancer-related fatigue, but not others, and that these effects persist well after treatment,” says lead author Julienne E. Bower, PhD. “This is critical for developing targeted treatments for this common and disabling symptom.” 🔗 Read the #OpenAccess article in Cancer: https://lnkd.in/eJF_aXm3 OncoAlert #BreastCancer #CancerFatigue #CancerResearch Full author list: Julienne E. Bower, PhD, Arielle Radin Pulverman, PhD, Patricia A. Ganz, MD, Michael R. Irwin, MD, Steve Cole, PhD, Laura Petersen, MS, Arash Asher, MD, Sara A. Hurvitz, MD, and Kate Crespi, PhD.

💗 October is Breast Cancer Awareness Month The American Cancer Society Journals proudly present the newly updated Breast Cancer Research Virtual Issue, showcasing research that matters to patients, clinicians, and the broader oncology community. From early detection and tailored therapies to survivorship care, this collection highlights progress, ongoing challenges, and opportunities to improve outcomes for those affected by breast cancer. 🔗 Explore the collection here: https://lnkd.in/eWFH2hND #BCAM #BCSM #BreastCancerAwareness #CancerResearch #Oncology #PatientCare

Interpreting trends in #ProstateCancer incidence are multifactorial; in this new editorial in CA: A Cancer Journal for Clinicians, Ruth Etzioni and Lukas Owens of Fred Hutch write about the many potential drivers and mechanisms by which disease control efforts play out in the population. Read their full response to American Cancer Society prostate cancer statistics by Tyler Kratzer et al. at https://lnkd.in/eSbtrXxG #PCSM @OncoAlert